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Transforming growth factor-β (TGF-β) signaling is involved in pathological processes following brain injury.
TGF-β signaling through Smad3 contributes significantly to the immune response and glial scar formation after
brain injury. However, TGF-β is also neuroprotective, suggesting that Smad3 signaling may also be involved in
neuroprotection after injury. We found expression of the TGF-β type II receptor (TβRII) and Smad3 protein to
be strongly and rapidly induced in neurons in the ipsilateral cortex and CA1 region of the hippocampus after
stab wound injury. In contrast, astrocytic expression of TβRII and Smad3 was induced more slowly. Comparison
of the response of wild-type and Smad3 null mice to cortical stab wound injury showed a more pronounced loss
of neuronal viability in Smad3 nullmice. Neuronal densitywasmore strongly reduced in Smad3 nullmice than in
wild-typemice at 1 and 3days post lesion in both the ipsilateral cortex and hippocampal CA1 region. Fluoro-Jade
B, TUNEL staining, and cleaved caspase-3 staining also demonstrated increased neuronal degeneration at early
time points after injury in the ipsilateral hemisphere in Smad3 null mice. Taken together, our results suggest
that TGF-β cytokine family signaling through Smad3 protects neurons in the damaged cortex and hippocampus
at early time points after injury.
Published by Elsevier Inc.
Introduction
Transforming growth factor-β (TGF-β) is widely recognized as a
critical regulator of key events in development, disease, and repair
(Dunker and Krieglstein, 2000; Massague, 1998). TGF-β regulates
inflammatory responses after injury in the peripheral and central
nervous system (CNS) (Wyss-Coray et al., 1997), and functions as a
survival factor for embryonic motoneurons, dopaminergic and neonatal
sensory neurons in vitro (Chalazonitis et al., 1992; Krieglstein et al.,
1995; Martinou et al., 1990; Poulsen et al., 1994). TGF-β exerts
neurotrophic effects on damaged neurons (Prehn et al., 1993), rescues
sympathetic neurons from death after destruction of the target
cells (Blottner et al., 1996), and protects dopaminergic neurons from
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity and cortical
neurons from sodium cyanide or glutamate (Farkas et al., 2003;
Krieglstein et al., 1995; Prehn et al., 1993). Further, antagonism of
TGF-β receptor signaling led to increased neurodegeneration in models
of either excitotoxic injury or Alzheimer's disease (Ruocco et al., 1999;
Tesseur et al., 2006). Thus, TGF-β signaling is critical for the brain
injury/repair response under a variety of different conditions.
TGF-β is induced after traumatic brain injury, and may act as a
neuroprotective factor in the injured CNS (Lindholm et al., 1992;
Logan et al., 1999b; Stoll et al., 2004). However, after brain injury TGF-
β is also responsible for deposition of extracellular matrix proteins
that contribute to glial scar formation (Logan et al., 1994, 1999a)
which retards neuronal regeneration (McKeon et al., 1995; Windle
et al., 1952) and increases the induction of traumatic epilepsy after
brain injury (Hoeppner and Morrell, 1986; Tian et al., 2005).
Additionally, TGF-β may suppress the early stages of neurogenesis
(Buckwalter et al., 2006; Wachs et al., 2006), which may reduce the
regenerative capacity of the brain. Thus, targeting TGF-β to enhance
recovery from traumatic injury becomes complex because of these
multiple and sometimes conflicting functions. It is therefore critical to
identify the TGF-β transduction pathways and downstream effectors
through which TGF-β mediates individual effects in an effort to target
specific pathways mediating detrimental effects while leaving its
beneficial effects unaltered.
Active TGF-β induces the formation of receptor hetero-tetramers that
contain two “type I” (TβR-I) and two “type II” (TβR-II) transmembrane
serine threonine kinase receptors (Vilar et al., 2006). TGF-β isoforms
elicit their specific responses through the ligand-induced formation
of a heteromeric receptor complex between TβR-I and TβR-II. TβR-II
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binds TGF-β first, and then recruits TβR-I, allowing for the
transphosphorylation-mediated activation of TβR-I. This ligand–receptor
activation leads to phosphorylation of Smad2 and Smad3 by the type I
receptor, and their release from a cytoplasmic protein (reviewed in
(Derynck and Zhang, 2003; Heldin et al., 1997; Krieglstein et al., 1995).
These receptors activate Smad proteins (R-Smads) which then form
heteromeric complexes with the pathway-independent Smad4 (Lagna
et al., 1996). The Smad complex translocates to the nucleus where it
regulates transcription of TGF-β target genes (Massague et al., 2005).
Smads interact with a diverse array of transcription factors to bring
about TGF-β regulated transcription (Feng and Derynck, 2005; ten
Dijke and Hill, 2004). However, although Smad proteins are critical to
many of the actions of TGF-β, TGF-β utilizes several different pathways
for signaling within cells, including Smad-independent pathways
(Farkas et al., 2003; Massague, 2003). Indeed, it has been proposed that
the neuroprotective effects of TGF-β may be transduced by the
alternative TβR-I, Alk1 signaling through NF-κB (Konig et al., 2005).
Smad proteins are involved in many of the same neuroprotective or
neurodegenerative processes that have been attributed to TGF-β,
suggesting that TGF-β signaling through Smad2 or Smad3 is critical for
many of these effects. Elevation of TGF-β levels after traumatic brain
injury correlate with local and rapid activation of Smad2/3-dependent
signaling in the lesioned brain (Lin et al., 2005). Activation of Smad3-
dependent signaling in astrocytes protects neurons against NMDA-
induced cell death (Docagne et al., 2002). Studies on Smad3 deficient
mice have revealed a role for Smad3 in trophic support for nigral
dopaminergic neurons (Tapia-Gonzalez et al., 2011), in addition to
maintenance of neurogenesis andmigration along the rostral migratory
stream to the olfactory bulb (Wang and Symes, 2010). Dysregulation of
TGF-β-Smad signaling by Tau hyperphosphorylation may contribute to
the neurodegeneration inherent in Alzheimer's disease (Baig et al.,
2009; Ueberham et al., 2006).
Our previous study showed that Smad3 deficient mice had reduced
scar formation and less immune infiltration after a traumatic brain
injury, suggesting a beneficial effect of Smad3 deficiency on recovery
(Wang et al., 2007). However, it remains unknown if Smad3 plays a
role in neuronal survival after traumatic brain injury. In the present
study, we used these Smad3 deficient mice to investigate the potential
neuroprotective role of Smad3 in the damaged cortex and hippocampus
after cortical stab wound injury.
Materials and methods
Animals
Mice homozygous for a targeted deletion in exon 8 of the Smad3
gene (Smad3ex8/ex8) and their wild-type littermates were bred
from heterozygous Smad3ex8/+ mice on a mixed C57BL/6 × SV129
background. All experiments were performed on mice between 2 and
3 months old. Genotype was determined by PCR analysis of genomic
DNA isolated from tail clippings at 3 weeks of age. Presence of the
wild-type Smad3 allele was established using primer 1: 5′-cca ctt cat
tgc cat atg ccc tg-3′ with primer 2: 5′-ccc gaa cag ttg gat tca cac-3′.
The targeted deletion was detected with primer 1 and primer 3: 5′-cca
gac tgc ctt ggg aaa agc-3′ (Yang et al., 1999). The protocols in this
study were approved by the USUHS IACUC and were in accordance
with the animal welfare guidelines of the Association for Assessment
and Accreditation of Laboratory Animal Care.
Stab injury
Cortical stab wound injury was carried out as previously described
(Wang et al., 2007). Briefly, mice were anesthetized with ketamine/
xylazine solution (50mg/kg ketamine/7.5mg/kg xylazine in 0.9% NaCl
solution) and placed in a stereotaxic frame. A 1.5-mm grove was drilled
in the cranium 2mm caudal to the Bregma, 1mm lateral to the midline.
A 1.1-mm sterile sharp knife was inserted vertically into the right
cerebral hemisphere 2mm deep to the dura surface. The knife was left
in situ for 1 min. The injury site was covered with sterile bone wax;
the skin incision was closed with sutures. At different times (1, 3, 7 or
14days post lesion (dpl))micewere deeply anesthetized then perfused
with ice-cold fresh 4% paraformaldehyde solution.
Preparation of tissue
Brains were fixed in 4% paraformaldehyde for 24 h at 4 °C,
cryoprotected in 10%, 20% and 30% sucrose for 24 h individually, then
quick frozen on dry ice and stored at −80 °C. 10 μm coronal sections
were cut sequentially through the entire lesion site on a cryostat,
mounted on gelatin coated glass slides and stored at−80 °C until use.
Six sections spaced 100 μm apart from each other through the width
of the lesion were mounted on each slide to provide evenly distributed
sections for each antibody stain.
Fluorescence immunohistochemistry
Sections taken from the−80°C freezerwerewashedwith 0.1% Triton
X-100 in 0.1M phosphate buffered saline (PBST), blocked in PBST/10%
normal goat serum (NGS) for 1 h, then incubated overnight at 4 °C in
PBST/1% NGS containing the primary antibody. Sections were then
washed in PBST three times and incubated with the corresponding
secondary antibodies for 2 h at room temperature. For double labeling
of Smad3/NeuN and Smad3/GFAP, the two primary antibodies were
incubated simultaneously with the sections, as were the correspondent
secondary antibodies after washing with PBST. Sections were rinsed
once with PBST followed by a distilled water rinse before coverslipping
with ProLong Gold antifade reagent (Invitrogen). The following primary
antibodieswere used: anti-NeuN (mousemonoclonal, 1:200, Millipore);
anti-GFAP (mouse monoclonal, 1:1000; Millipore); anti-TβRII (rabbit
polyclonal, 1:15,000; Santa Cruz Biotech); anti-Smad3 (rabbit polyclonal,
1:100; Upstate); and anti-pSmad3 (rabbit polyclonal, 1:1000, Cell
Signaling). Secondary antisera were either anti-mouse or anti-rabbit
IgG conjugated to Alexa Fluor 488 or Alexa Fluor 568 (1:1000,
Invitrogen). Sections were also incubated with secondary antisera
alone to control for non-specific binding of the secondary antiserum to
the mouse brain sections. For costaining of Smad3/TβRII and pSmad3/
TβRII, staining was performed sequentially, as both primary antibodies
were raised in rabbit. Sections were blocked overnight in PBST/10%
NGS before overnight incubation with the first primary antiserum in
PBST/1% NGS. After washing, sections were incubated with the
corresponding secondary antiserum for 2 h, before blocking again
(PBST/10% NGS) overnight to avoid cross-reactivity. Incubation with
the second primary antiserum was again performed overnight in
PBS/1% NGS before a 2h incubation with the second secondary. Sections
were washed with PBS followed by rinsing in distilled water before
coverslipping with ProLong Gold antifade reagent. Images (20×) were
acquired using an Olympus BX61 fluorescence microscope attached to
a Retiga EXi Aqua CCD camera (Qimaging), using iVision software
(BioVision Technologies). For colocalization studies, double-stained
cells were analyzed using a Zeiss confocal-laser scanning microscope
(LSM 510) equipped with argon and He/Ne laser emitting at 488 nm
and 568nm.
Assessment of cell damage
Fluoro-Jade B histofluorescence was performed as described
(Schmued et al., 1997). Briefly, brain sections were removed from the
−80 °C and left at room temperature for 20 min. Sections were
sequentially immersed in 100% ethyl alcohol (3 min), 70% alcohol
(1 min) then water (1 min). They were then immersed in 0.06%
potassium permanganate for 15 min while shaking gently. After a
distilled water rinse they were transferred to the 0.001% Fluoro-Jade B
staining solution for 30 min. Sections were rinsed three times with
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distilled water, dried and the slides immersed in xylene and coversliped
with DPX mounting media (Aldrich Chem. Co., Milwaukee, WI).
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)
assay. The TUNEL reaction preferentially labels DNA strand breaks
generated during apoptosis. Sections were first labeled with anti-
NeuN to determine the amount of neuronal apoptosis. Brain sections
were washedwith 0.1% Triton X-100 in 0.1M phosphate buffered saline
(PBST), blocked in PBST/10% normal goat serum (NGS) for 1 h, then
incubated overnight at 4 °C in PBST/1% NGS containing anti-NeuN.
Sections were then washed in PBST three times and incubated with
anti-mouse secondary antibody for 2 h at room temperature. Sections
were permeabilized with PBST and subsequently washed with PBS at
room temperature. Then, the area around the brain section was dried
and added to the TUNEL reaction mixture (fluorescence In Situ Cell
Death Detection Kit, Roche, IL, USA) consisting of 50μl enzyme solution
(vial 1) and 450μl label solution (vial 2). Brain sections were incubated
at 37 °C for 60 min in the dark. Sections were then washed with PBS
followed by a distilled water rinse before coverslipping with ProLong
Gold antifade reagent.
Quantification and statistical analysis
Immunohistochemistry or Fluoro-Jade B staining was performed on
sections spaced at 100μm from each other throughout the width of the
lesion. The total number of Fluoro-Jade B cells in the contralateral and
ipsilateral cortex and hippocampus were counted in each of 5–6
sections for each animal (100 μm interval), for each of 6 animals and
averaged. NeuN, Smad3, and TβRII immunoreactive cells were counted
in the area adjacent to the lesion cavity within a 0.01 mm2 window
(100 μm × 100 μm) in the cortex and a 0.04 mm2 window
(200 μm× 200 μm) in the hippocampal CA1, for each of 5–6 sections
(100 μm interval) per animal and subsequently averaged. The intensity
of immunohistochemical signal in the Smad3+ or NeuN + cells was
measured with metamorph software (Molecular Devices, Sunnydale,
CA). Individual cellular Smad3 and NeuN immunoreactive intensity
was determined through outlining the region around each cell,
thresholding the image and subtracting the background from the
intensity reading (Mokin and Keifer, 2006). All exposure parameters
remained identical during image capture. Data are presented in gray
scale values. For statistical analysis, the cell number or the gray level
value was averaged from all the sections measured for each mouse.
Differences between wild-type (+/+) and Smad3 null (−/−) mice at
different time points were determined by two-way ANOVA with
Bonferroni of Sidak corrections for multiple comparisons (Prism 6
software, Graphpad). All other comparisons were calculated by one-
way ANOVA using the Bonferroni multiple comparison test.
Results
TβRII expression is rapidly induced in neurons in the cortex and
hippocampus after stab wound injury
TβRII is the specific type II ligand binding receptor subunit for TGF-β
and is absolutely required for TGF-β signal transduction whereas there
are at least 2 type I receptors that can complex with TβRII to transduce
TGF-β signals (de Caestecker, 2004). As we have previously shown
induction of TGF-β after stab wound injury in mice (Wang et al.,
2007), we examined expression of TβRII to determine which cells in
the cortex and hippocampus were able to respond to the induced
TGF-β. The injury we used, stab wound injury (SWI) to the cerebral
cortex, is a penetrating injury that induces strong local changes in
inflammation and astrocytic responses (Wang et al., 2007). We found
that TβRII was upregulated on NeuN+neurons in the ipsilateral cortex
(Fig. 1e, f) at 1 dpl in comparison to expression in the contralateral
hemisphere (Fig. 1a, b). TβRII expression was induced in cortical layers
III–VI and was located within the soma of neurons (Fig. 1f3–6). In the
ipsilateral hippocampus at 1 dpl, TβRII was upregulated specifically in
CA1 neurons, in the cell soma (Fig. 1g, h, h1–6), while there were only
sporadic TβRII expressing neurons in the contralateral CA1 region (Fig.
1c, d). At 1 dpl, TβRII was not widely expressed in astrocytes (data not
shown), but its expression was induced in reactive astrocytes by 7 dpl
(Fig. 4). TβRII was also expressed in astrocytes starting to form the
glial scar at the border of the lesion at 7 dpl (Fig. 4a). These results
suggest that neurons, by upregulating TβRII expression, are able to
respond to TGF-β at early time points after injury. The astrocytic
expression of TβRII occurred at later time points, suggesting a delayed
astrocytic response to TGF-β in this model of traumatic brain injury
(Table 1).
Smad3 expression is induced in cortical and hippocampal neurons after
injury
To determine whether Smad3 may be involved in the neuronal
response to TGF-β after injury, we examined Smad3 expression in the
cortex and hippocampus at different time points post lesion. In the
normal mouse brain, we found very low Smad3 expression in cortical
and hippocampal neurons (data not shown). In the ipsilateral cortex
Smad3 was strongly expressed in neurons throughout cortical layers
III–VI (Fig. 2d, e–h, Table 1) at 1 and 3dpl. However, Smad3 wasmostly
localized in the cell soma in these neurons, with only occasional nuclear
immunoreactivity (Fig. 2f1–3). To determine whether activated Smad3
was localized in the nucleus we utilized an antibody against
phosphorylated Smad3, pSmad3. Staining for pSmad3 showed mainly
nuclear localization (Fig. 2n1–2). This staining was induced in the
ipsilateral cortex at 1 dpl (Fig. 2l–n) indicating that injury initiates
Smad3 phosphorylation and translocation to the nucleus. In contrast,
in the contralateral hemisphere, Smad3 and pSmad3 staining was
observed in only a few neurons (Fig. 2a–c, i–k). The intensity of
Smad3 immunoreactivity was doubled in the ipsilateral cortex and
hippocampus at 1 and 3dpl, returning to baseline levels by 7dpl (Figs.
2h and 3h). Interestingly, Smad3 immunoreactivity was also induced
in the contralateral hippocampus at 1 dpl (Fig. 3g), but not at later
time points (3 and 7 dpl, data not shown). Most Smad3+ cells also
expressed TβRII in the ipsilateral cortex (Fig. 2o–q),with the percentage
of colabelled Smad3+/TβRII+ cells increasing from 67% to 86% of the
total Smad3+ cells from 1 to 14 dpl (Fig. 2r). The percentage of
pSmad3+/TβRII+ cells also increased with time after injury, although
at 1 dpl approximately 40% of pSmad3+ cells also expressed TβRII
increasing to 93% of the total pSmad3+ cells by 7 dpl (Fig. 2w).
Similarly, in the ipsilateral hippocampal CA1 region the vast majority
of Smad3+ or pSmad3+ cells coexpressed TβRII, with the percentage
of Smad3+/TβRII+ cells increasing with time after injury (Fig. 3r, w).
Taken together these data suggest that TGF-β signaling through
Smad3 in neurons is important to the early neuronal response to injury.
Smad3 expression in reactive astrocytes and glial scar after injury
Astrocytes respond to traumatic injury by becoming activated. If the
injury is sufficiently severe, then these reactive astrocytes participate in
many processes that lead to the formation of a glial scar (Sofroniew,
2009). We have previously shown that the absence of Smad3 in mice
leads to reduced and more rapid scar formation implicating Smad3
signaling in the process of glial scar formation (Wang et al., 2007). In
our stab wound injury model, we detect Smad3 and pSmad3 in
GFAP+ reactive astrocytes in the cortex at 3dpl with a peak expression
at 7dpl (Fig. 4, Table 1), corresponding with the degree of hypertrophy
of the reactive astrocytes. Astrocytic Smad3 expression had almost
disappeared by 14 dpl when the reactive astrocytes had the
morphology of tangled processes and indistinguishable cell bodies
forming part of the glial scar ((Wang et al., 2007) and data not
shown). In our hands, Smad3 expression in astrocyteswas undetectable
by immunohistochemistry in the normal brain, in the contralateral
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hemisphere at all time points examined and at 1 dpl in the ipsilateral
hemisphere (data not shown). Smad3 expression in hippocampal
astrocytes was also strongest at 7 dpl (Fig. 4) corresponding to the
greatest GFAP expression. However, in the hippocampus even at 7 dpl
Smad3 was only expressed in a few astrocytes, and was weak at other
time points (Table 1). These data suggest that astrocytic induction of
Smad3 expression was delayed relative to that of neurons.
Smad3 deficiency decreases neuronal viability in the cortex and
hippocampal CA1 region
To determinewhether Smad3 has a functional role in neuroprotection
after injury, we compared neuronal viability after TBI between wild-type
and Smad3 null mice. Traumatic brain injury causes neuronal damage in
cortical and hippocampal regions that can be determined by NeuN
density (Collombet et al., 2006; Unal-Cevik et al., 2004). We therefore
quantified the number and intensity of NeuN+ cells around the lesion
core in injured mice and in the corresponding area in naïve (control)
mice in both wild-type and Smad3 null mice. Stab wound injury led to a
reduction in NeuN cell number and intensity in wild-type and Smad3
null mice (Fig. 5). However, the loss of NeuN staining was significantly
greater in Smad3 null mice than wild-type mice. After injury, at 1 dpl,
NeuN+ cell number was reduced 28% in wild-type mice and
approximately 60% in Smad3 null mice as compared with the control
wild-type and Smad3 null mice respectively. At 7 dpl, the NeuN+ cell
number was reduced approximately 45% in wild-type mice and about
75% in Smad3nullmice (Fig. 5e). The intensity of NeuN immunoreactivity
was also more strongly reduced in Smad3 null mice in comparison to
Fig. 1. Increase in TβRII expression in the ipsilateral (Ip) cortex and hippocampus after stab wound injury. (a–h) TβRII staining in the ipsilateral cortex (e, f) and hippocampus (g, h) in
comparison to the contralateral cortex (a, b) and hippocampus (c, d). At 1dpl, TβRII expression (red) is increased in neurons (NeuN, green) in the ipsilateral cortex (e, f) and hippocampal
CA1 region (g, h). Higher power images are shown of the boxed area of the ipsilateral cortex (f1-2) and the hippocampal CA1 region (h1-2). Arrowhead in f1 points to cell shown in f3–f6.
Arrowhead in h1 corresponds to cell shown in h3–h6. There is little detectab. TβRII expression in the contralateral (Cl) cortex (cx) (a) or hippocampal CA1 (c) where the number of
neurons is abundant (b and d). Scale Bars: 20 μm (f3-6, h3–h6,), 50 μm (a–h, f1, f2, h1, h2).
Table 1
Colocalization of TβRII, Smad3 and pSmad3 with astrocytic and neuronal markers in the
cortex and hippocampal CA1 region in control and injured brains at different times post
lesion (dpl).
Control 1 dpl 3 dpl 7 dpl 14 dpl
CX CA1 CX CA1 CX CA1 CX CA1 CX CA1
Neurons (NeuN +)
TβRII − − +++ +++ +++ +++ ++ ++ + +
Smad3 + + +++ +++ ++ ++ + + + +
pSmad3 +/− +/− ++ ++ + + + + +/− +/−
Astrocytes (GFAP +)
TβRII − − − − + + ++ ++ + +
Smad3 − − − − + + ++ ++ + +
pSmad3 − − − − +/− +/− + + + +
The degree of colocalization is graded as:
−: negative ±: occasional +: low ++: intermediate +++: strong.
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wild-type mice. NeuN immunoreactivity was reduced only at 1 dpl
(approximately 30%) in wild-type mice, but reduced at 1 and 3 dpl
(about 70% reduction at 1dpl and 30% reduction at 3dpl) in Smad3 null
mice (Fig. 5f). There was no difference in either the NeuN+ cell number
or intensity between control wild-type and Smad3 null mice (Fig. 5e, f),
nor did we find any obvious change of NeuN immunoreactivity in the
contralateral cortex (data not shown).
In the hippocampus, Smad3 null mice displayed a dramatic
reduction of viable neurons after stab wound injury with almost a
complete disappearance of NeuN immunoreactivity at 1 dpl and a
Fig. 2. Increase in Smad3 and pSmad3 expression and colocalization with TβRII in the cortex of wild-type mice after injury. Coronal sections were immunostained for either Smad3 or pSmad3
(red) together with either a neuronal (NeuN) marker or the TGF-β receptor, TβRII (green). (a–f) At 1 day post lesion (dpl), there was decreased neuronal density in the ipsilateral (Ip)
cortex (d) in comparison to that in the contralateral (Cl) cortex (a). Immunostaining for Smad3 was dramatically increased in the ipsilateral cortex (e) around the injury site,
predominantly in NeuN + neurons (merged images f, and high magnification f1–f3 with orthogonal projections in f3). (i–n) pSmad3 staining was increased in the ipsilateral cortex
specifically in neuronal nuclei as compared to the mainly cytoplasmic neuronal staining of total Smad3 (compare n to f). (g) Quantification of Smad3 expression in the ipsilateral or
contralateral cortex at 1 dpl, relative to that in control mice. (h) Time course of intensity of Smad3 expression in the ipsilateral cortex shows that the peak expression occurred at 1
and 3 dpl (mean± SEM, n=6), ****p b 0.0001; ***p b 0.001 compared to control. (o–v) TβRII colocalizes in cells expressing Smad3 (o–q) and pSmad3 (s–v) in the ipsilateral cortex at
1 dpl. (r, w) Quantification of the cells expressing TβRII together with Smad3 (r) or pSmad3 (w) as a percentage of the total number of Smad3 or pSmad3 expressing cells. Scale Bars:
20 μm (f1-3, n1-2), and 50 μm (a–v).
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reduction at 3 and 7 dpl in the ipsilateral CA1 area (Fig. 6). Wild-type
mice showed a significant, but far smaller decrease in both NeuN
number and intensity in the ipsilateral CA1 only at 1 dpl (Fig. 6i, j). In
the contralateral CA1, Smad3 null mice showed reduced NeuN
immunoreactivity only at 1 dpl, with no decrease in the number of
NeuN+ cells (Fig. 6e, f, j). Smad3 null mice did not show any reduction
Fig. 3. Increase in Smad3 and pSmad3 expression and colocalization with TβRII in the hippocampus of wild-type mice after injury. Coronal sections were immunostained for either Smad3 or
pSmad3 (red) together with either a neuronal (NeuN) marker or the TGF-β receptor, TβRII (green). (a–f) At 1 day post lesion (dpl), there was decreased NeuN staining (green) in the
ipsilateral CA1 (d) in comparison to the contralateral CA1 (a). Smad3 staining colocalized with neuronal staining in the soma (merged image in f), although some neurons displayed
nuclear Smad3 expression (high magnification in f1-3, and orthogonal projection in f3). (g) Intensity of Smad3 staining at 1 dpl showing elevated Smad3 expression in the ipsilateral
and contralateral CA1. (h) Time-course of intensity of Smad3 expression (mean±SEM, n=6), ****pb 0.0001; ***pb 0.001, **pb 0.01 compared to control. (i–n) At 1dpl pSmad3 staining
was increased in the ipsilateral CA1 specifically in neuronal nuclei as compared to themainly cytoplasmic neuronal staining of total Smad3 (compare n to f). Arrowhead in n corresponds to
cell shown in n1. (o–q) In the ipsilateral CA1, TβRII colocalizes in cells expressing Smad3 at 1dpl (high magnification in q1). (s) Some TβRII/pSmad3 colocalization is still detectable at 14
dpi. Arrowhead in s corresponds to cell shown in s1-3. (r, t) Quantification of TβRII expression together with Smad3 (r) or pSmad3 (t) as a percentage of the total number of Smad3 or
pSmad3 expressing cells. Scale Bars: 20 μm (f1-3, n1, q1, s1), and 50 μm (a–s).
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in NeuN + cell numbers in the ipsilateral or contralateral CA3 or DG
regions (data not shown). Early loss of NeuN immunoreactivity could
be due to damage to neurons that subsequently recover (Collombet
et al., 2006; Unal-Cevik et al., 2004). We therefore examined Nissl
staining of sections taken from mice at 7 dpl. This staining confirmed
significant neuronal loss in the ipsilateral CA1 region of Smad3 null
mice, with a less pronounced but still detectable loss in this region in
wild-type mice (Fig. 6c, d, g, h). There were also slightly reduced
neuronal numbers in the ipsilateral cortex only in the Smad3 null
mice (data not shown). However, cresyl-violet staining did not
reveal any neuronal loss in the contralateral CA1 in Smad3 null
mice in comparison to wild-type mice (Fig. 6g, h). These data suggest
that, after injury, Smad3 deficiency leads to increased neuronal
death in the ipsilateral cortex and hippocampus close to the cortical
lesion site.
Absence of Smad3 protein results in increased neuronal degeneration after
injury
We next determined whether Smad3 deficiency altered the
number of neurodegenerative neurons in the cortex and hippocampus
after stab wound injury by examining Fluoro-Jade B staining in wild-
type and Smad3 null mice. Fluoro-Jade B is a specific fluorescentmarker
for degenerating neurons (Schmued et al., 1997; Schmued andHopkins,
2000) and has been widely used to detect neuronal degeneration
induced by different types of insults (Moreira et al., 2007; Riba-Bosch
and Perez-Clausell, 2004; Sun et al., 2007). In wild-type mice stab
wound injury caused significant Fluoro-Jade B staining in the ipsilateral
cortex (Fig. 7) and hippocampal CA1 region (Fig. 8) at 1 and 3 dpl.
However, in sections taken from Smad3 null mice there were
significantly more Fluoro-Jade B labeled degenerating neurons in both
cortex and CA1 at both 1 and 3 dpl (Figs. 7 and 8). These data show
that the absence of Smad3 led to increased neuronal degeneration
after injury. No neuronal degeneration was detected in the CA3 region
or the dentate gyrus (DG) of the hippocampus (data not shown).
We also found no Fluoro-Jade B staining in the contralateral cortex
or hippocampus at any time point after injury (data not shown).
To determine whether the neurons were dying by apoptosis, we
assessed cell death using a TUNEL assay (to measure nuclear DNA
fragmentation) in the injured cortex of both wild-type and Smad3 null
mice. We co-stained with NeuN to show that these dying cells were
predominantly neurons. We detected a clear increase in TUNEL+ cells
in the ipsilateral cortex surrounding the lesion of wild-type mice
(Fig. 7f). However, there were clearly more TUNEL+ cells in the
ipsilateral cortex (Fig. 7f, g) and CA1 region (Fig. 8h, i) of Smad3 null
mice in comparison to wild-type mice. TUNEL+ cells displayed typical
Fig. 4. Astrocytic expression of TβRII and Smad3 in wild-type mice at 7 days post lesion. (a) Astrocytic TβRII (red) expression colocalizes with GFAP+ reactive astrocytes (green) in the
ipsilateral cortex. Circle in a is shown in inset in a1 and a2. Arrows in a show the beginning of the formation of glial scar. (b) Smad3 expression is localized to some reactive astrocytes
in the injured cortex. Strong cytoplasmic Smad3 (b, b1-4) andnuclear pSmad3 (c, c1-4) immunoreactivity is detected in astrocytes at the lesion border (c). Circled cells are shown inhigher
magnification in adjacent panels. Smad3 (d, d1) and pSmad3 (e, e1) were also localized in reactive astrocytes (GFAP) in the ipsilateral hippocampus. Scale Bars: 50μm (a, b, b1, c, c1, d, e)
and 20 μm (a1-2, b2-4, c2-4, d1, e1).
359S. Villapol et al. / Experimental Neurology 250 (2013) 353–365
apoptotic morphology showing apoptotic bodies and condensed
chromatin (Fig. 7g1–3). The involvement of the caspase pathway
was demonstrated with the colocalization of cleaved caspase-3
(Fig. 7i1–3). Thus, our data show that Smad3 ablation led to increased
neuronal death by apoptosis in the ipsilateral cortex and hippocampus
at early time points after stab wound injury.
Fig. 5. Loss of viable neurons in the injured cortex of Smad3 deficient mice. Attenuated neuronal density (NeuN, in green) around the lesion core in the cortexwas observed in Smad3 nullmice
(−/−) compared to wild-type (+/+) mice at 1 day post lesion (dpl) (a, a1, b, b1) and 7 dpl (c, c1, d, d1). (e) No difference was found between genotypes in the number of neurons
(NeuN+ cells) in control mice but a significant reduction in the number of neurons was found at 1, 3 and 7 dpl in Smad3 null mice. (f) The intensity of NeuN staining was decreased in
wild-type mice only at 1 dpl, but at 1 and 3 dpl in Smad3 null mice. At 1 and 3 dpl Smad3 null mice showed a lower NeuN intensity than wild-type mice (mean ± SEM, n = 6);
***p b 0.001, **p b 0.01, *p b 0.05 compared to control wild-type mice; ####p b 0.0001, ##p b 0.01 compared to control Smad3 null mice; ++++p b 0.0001, +p b 0.05 compared to injured
wild-type mice. Scale Bars: 100 μm (a-d), 50 μm for (a1, b1, c1, d1).
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Discussion
After stab wound injury, mice that do not express the TGF-β-
regulated transcription factor Smad3, show greater loss of neurons in
the cerebral cortex as well as the CA1 area of the hippocampus
compared to wild-type mice. This increased neuronal damage is
manifest during the acute injury phase (1 and 3 dpl), which coincides
with increased neuronal expression of the TGF-β type II receptor,
TβRII, in wild-type mice. Smad3 is also induced in neurons at these
early time points after injury in wild-typemice. Interestingly, astrocytic
expression of TβRII and Smad3 protein was strongly induced in the
ipsilateral cortex and CA1 region of the hippocampus only at a later
time point, by 7 dpl. Taken together, our results suggest that TGF-β
related cytokines signaling through Smad3 protect neurons in the
damaged cortex and hippocampus during the acute injury response.
Smad3 signaling involved in neuroprotection may be initiated by TGF-β
Several lines of evidence demonstrate that TGF-β is a potent
neuroprotective agent. TGF-β protects neurons in many models of
neurodegenerative diseases, e.g. amyotrophic lateral sclerosis (ALS)
(Day et al., 2005), Huntington's disease (Battaglia et al., 2011),
Alzheimer's disease (Caraci et al., 2011), Parkinson's disease
(Gonzalez-Aparicio et al., 2010) and status epilepticus (Li et al., 2013).
TGF-β1 knock-out mice show prominent neuronal cell death in various
parts of the brain (Brionne et al., 2003), and genetic reduction of TGF-β2
leads to a loss of dopaminergic neurons in mice (Andrews et al., 2006).
Cell culture studies have also shown that TGF-β signaling is required for
maintaining neuronal survival after various insults (Bruno et al., 1998;
Walshe et al., 2011; Zhu et al., 2002). Inhibition of TGF-β signaling
specifically in neurons leads to increased neurodegeneration (Tesseur
et al., 2006). Our data show that ablation of Smad3, a critical mediator
of TGF-β signaling, caused significantly more neuronal loss after injury.
The time course of neuronal death correlated with the timing of
elevated neuronal Smad3 expression in wild-type mice. It has also
previously been shown that TGF-β1 is strongly elevated acutely
after traumatic injury in mice (Chen et al., 2011). Thus, there is strong
evidence that TGF-β signaling through Smad3 may be promoting
the suggested neuroprotection in this injury model. However,
other TGF-β superfamily cytokines including activins, nodal and GDFs
can also initiate Smad3 signaling (Massague et al., 2005), and activin
has neuroprotective properties in vitro and in vivo (Sulyok et al.,
2004; Tsuchida et al., 2009). These related cytokines differ in the
receptors that they use to activate Smad3. Activin, nodal and GDF11
utilize Activin Receptor IIB as their ligand binding subunit, which
complexes together with type I receptors (ALK-4, ALK-7 and ALK-5
respectively) to form a functional signaling unit (Andersson et al.,
2006; Kumar et al., 2001; Labbe et al., 1998). TGF-β is the only known
cytokine to signal through TβRII (Massague, 2000). Thus, although we
cannot exclude the role of TGF-β related cytokines in contributing to
the effects we report, the co-expression of TβRII and Smad3 in the
majority of Smad3+ cells (Figs. 2 and 3), together with the known
effects of TGF-β on neuroprotection imply that TGF-β signaling through
Smad3 may be a major regulator of neuroprotection after stab injury.
Fig. 6. Loss of viable neurons in the injured hippocampal CA1 region of Smad3 deficient mice. (a,b) A dramatic decrease in NeuN immunoreactivity in the ipsilateral CA1 area was found in
Smad3 null mice (−/−) compared to wild-type (+/+) mice at 1 day post lesion (dpl) (also shown in i). (j) The intensity of NeuN staining in Smad3 null mice in the ipsilateral CA1
was significantly different from wild-type mice at 1, 3 and 7 dpl but not in control mice. In the contralateral CA1, Smad3 null mice had reduced NeuN intensity only at 1 dpl. (mean±
SEM, n=5-6), **p b 0.01 compared to control wild-type mice; ####p b 0.0001, ###p b 0.001 compared to control Smad3 null mice; ++++p b 0.0001, +++p b 0.001 compared to injured
wild-typemice. (c–h)Cresyl-violet staining of 7dpl hippocampi showeda reduced neuronal density in the ipsilateral CA1 region in both genotypes, although amore pronounced reduction
in Smad3 null mice (d). Scale Bars: 50 μm (a, b, e, f) and 400 μm (c, d, g, h).
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Mechanism of TGF-β mediated neuroprotection
The mechanisms throughwhich Smad3 canmediate neuroprotection
are not clear. TGF-β activation of Smad3 is through activation of the
kinase activity of ALK-5, TβR1. However, it has previously been shown
that TGF-βmediated neuroprotection of cultured cortical or hippocampal
neurons is through activation of ALk1-NF-κB anti-apoptotic signaling
(Konig et al., 2005). Our data suggest that Smad3 is also capable of
promoting neuroprotection. Indeed, a different line of Smad3 null mice
have reduced neuronal survival of dopaminergic neurons (Tapia-
Gonzalez et al., 2011). These mice also have reduced phosphorylated
Erk in dopaminergic neurons but not in other brain areas, suggesting
that there may be specific interactions between Smad3 and Erk signaling
in stressed neurons. Inhibition of Smad3 in neuroblastoma cells, through
transfection of dominant negative Smad3, also leads to reduced cell
survival, while constitutively active Smad3 can rescue the decrease in
cell viability caused by decreased TGF-β receptor signaling (Tesseur
et al., 2006). Thus, taken together there is significant evidence that
TGF-β signaling through Smad3 enhances neuronal survival.
Hippocampal neuronal loss after stab wound injury
Wedetected dramatic neuronal degeneration in the hippocampal CA1
area ipsilateral to the injury side though our brain injury has no direct
injury to the hippocampus (Wang et al., 2007). Previous reports have
shown that a controlled cortical impact injury can also cause a significant
neuronal loss in the CA1 and CA3 regions of the hippocampus (Anderson
et al., 2005; Zhao et al., 2012). Hippocampal neurons are extremely
vulnerable to different types of insults (Bonner et al., 2010; Tsuchiya
et al., 2011). However, after stab wound injury we found little neuronal
cell death in the dentate gyrus of the hippocampus (data not shown), in
disagreement with other injury models which resulted in significant
neuronal death in this region (Zhao et al., 2012). It has previously been
suggested that the most vulnerable neurons of the hippocampus are the
immature neurons of the subgranular zone of the dentate gyrus (Gao
and Chen, 2009), which we did not find to be affected by this injury.
Thus, there does seem to be differential vulnerability of specific neuronal
populations to different models of injury.
Absence of Smad3 makes the contralateral hippocampal CA1 neurons
damaged after stab wound injury
Interestingly, we observed that NeuN immunoreactivity in the
contralateral CA1was significantly reduced in Smad3 nullmice compared
to wild-type mice at 1 dpl (Fig. 5j). This difference was no longer
detectable by 3 dpl. Multiple studies have demonstrated that the early
loss of NeuN immunoreactivity, a specific marker of mature neurons,
can be used to determine reversible neuronal damage (Collombet et al.,
2006; Unal-Cevik et al., 2004). NeuN immunoreactivity relies on the
antigenicity of the NeuN antigen that can be altered after injury, but
Fig. 7. Cortical neuronal death is increased in Smad3 deficient mice after brain injury. (a–d) Increased numbers of degenerating neurons indicated by Fluoro-Jade B (FJB) staining (in green)
around the cortical impact site in Smad3 null mice (−/−) compared to wild-type mice (+/+) at 1 and 3 days post lesion (dpl) (a1–d1 are enlargements of the boxed areas in their
respective figures). These data are shown graphically in (e). (f, g) Increased TUNEL staining in Smad3 nullmice confirmed the increased neuronal death in thesemice. Highmagnification
of the square area in (g) shows TUNEL+ neurons (g1 in green), NeuN (g2 in red) and colocalization (g3). Pro-apoptotic cleaved caspase-3 (i1 in green) was localized in the nucleus of
neurons (i2, NeuN in red, i3 merged image) within the cortical site of the injury. Arrowheads indicate the extent of degenerating neurons (a–d, f, g). (mean ± SEM, n = 6),
****p b 0.0001; *p b 0.05 compared to injured wild-type mice. Scale Bars: 20 μm (g1-3, i1-3), 150 μm (a1–d1), 300 μm (f, g), and 500 μm (a–d).
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neurons with reduced NeuN immunoreactivity may still be able to
recover. Our finding of reduced NeuN immunoreactivity at 1 dpl in
Smad3 null mice but not at 3 dpl indicates that these neurons in
the hippocampal CA1 contralateral to the injury were damaged but
not destroyed. Our data therefore highlight the injury-induced
enhanced vulnerability of this neuronal population in the contralateral
hippocampus and show that Smad3 signaling in these neurons is
neuroprotective.
Does activation of Smad3 in glial cells contribute to the neuroprotective
effect of Smad3?
Injury induces neuronal Smad3 expression in the ipsilateral cortex
and hippocampus, at early time points after injury in wild-type mice
(Figs. 2 and 3). Astrocytic expression of Smad3 is not detectable until
3 dpl. As neuronal degeneration peaks at 1 dpl, it is likely that Smad3
expression in neurons is directly neuroprotective at early time points.
There are more than twice as many degenerating neurons in Smad3
null mice than in wild-type mice at 1 and 3 dpl, suggesting that the
lack of Smad3 specifically in neurons is detrimental for neuronal
survival. The lack of an early astrocytic Smad3 response is in agreement
with our previously report that there was no difference between wild-
type and Smad3 null mice in the number of GFAP+ astrocytes at
3 dpl, but a significant difference at 7 dpl (Wang et al., 2007). Thus, at
later time points after stab wound injury, Smad3 signaling within
astrocytes may contribute to a non-cell autonomous effect on neuronal
survival. Indeed, Smad3 signaling in cultured astrocytes is known to
be important for specific astroglial responses that support neuronal
Fig. 8.Hippocampal neuronal death is increased in Smad3 deficient mice after brain injury. Increased numbers of degenerating neurons indicated by Fluoro-Jade B (FJB) staining (in green) in
the hippocampus of Smad3 null mice (−/−) compared to wild-type mice (+/+) at 1 and 3 days post lesion (dpl). These data are shown graphically in (g). (mean ± SEM, n = 6),
***p b 0.001; *p b 0.05, compared to injured wild-type mice. An increase in apoptotic neurons (TUNEL+ cells in green, and NeuN in red) was detected in the CA1 region in the Smad3
null mice (−/−) (i) compared to wild-type Smad3 mice (+/+) (h) at 1 dpl. Scale bar=20 μm (h, i) and 100 μm (a–f).
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survival, such as up-regulation of plasminogen activator inhibitor type 1
(PAI-1) (Docagne et al., 2002). Smad3 action in astrocytes is also
important in promoting expression of genes and protein that are critical
for glial scar formation such as induction of some chondroitin sulfate
proteoglycan genes (Susarla et al., 2011). Therefore, the delayed
elevation of Smad3 expression in astrocytes may be more important
for promotion of reactive gliosis leading to glial scar formation rather
than the promotion of neuron survival after injury.
We have previously shown that the Smad3 nullmice respond to stab
wound injury with reduced glial scar formation, and less infiltration of
neutrophils and macrophages (Wang et al., 2007). We show here
however, increased neuronal degeneration and death in the ipsilateral
cortex and hippocampus in these Smad3 mice after the same injury.
Our data point once again to the complex reactions that TGF-β or related
cytokines can elicit, and the necessity of understanding all of the
downstream actions of these context dependent cytokines. Initially,
we sought to differentiate beneficial from detrimental effects through
delineating specific intracellular signaling pathways. However, our
data show that Smad3 signaling may mediate both neuronal survival
and promotion of scar formation. As thesemice are complete knockouts,
it is still possible, that cell-specific conditional inducible knockouts may
be able to show beneficial effects through deletion of Smad3 in only one
cell type in the adult. Our data suggest that caution is required in
utilizing any therapeutic that seeks to globally inhibit TGF-β signaling
within the CNS.
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